Nexalin Technology, Inc. (NASDAQ: NXL) Stock Competitors & Peer Comparison
See NXL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NXL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NXL | $4.28 | -1.61% | 3.1M | -9.11 | -$0.47 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $98.83 | -2.10% | 171B | 18.97 | $5.21 | +2.51% |
| MDT | $86.29 | -0.92% | 110.5B | 15.61 | $5.53 | +3.31% |
| SYK | $275.39 | -1.21% | 105.6B | 20.58 | $13.39 | +1.27% |
| BSX | $43.65 | -0.52% | 64.9B | 14.09 | $3.10 | N/A |
| EW | $86.32 | -2.00% | 49.7B | 31.99 | $2.70 | N/A |
| DXCM | $86.29 | -0.40% | 32.6B | 33.84 | $2.55 | N/A |
| GEHC | $65.37 | -1.64% | 29.5B | 14.34 | $4.56 | +0.21% |
| PHG | $24.43 | -1.37% | 23.9B | 13.96 | $1.75 | +4.04% |
Stock Comparison
Boston Scientific Corporation (NYSE: BSX-PA)
NXL vs BSX-PA Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NXL's ROE is -2.78%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NXL is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BSX-PA's competition here
Abbott Laboratories (NYSE: ABT)
NXL vs ABT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ABT has a market cap of 171B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ABT trades at $98.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ABT's P/E ratio is 18.97. In terms of profitability, NXL's ROE is -2.78%, compared to ABT's ROE of +0.11%. Regarding short-term risk, NXL is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ABT's competition here
Medtronic plc (NYSE: MDT)
NXL vs MDT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, MDT has a market cap of 110.5B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while MDT trades at $86.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas MDT's P/E ratio is 15.61. In terms of profitability, NXL's ROE is -2.78%, compared to MDT's ROE of +0.11%. Regarding short-term risk, NXL is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
NXL vs SYK Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SYK trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SYK's P/E ratio is 20.58. In terms of profitability, NXL's ROE is -2.78%, compared to SYK's ROE of +0.16%. Regarding short-term risk, NXL is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
NXL vs BSX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BSX has a market cap of 64.9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BSX trades at $43.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BSX's P/E ratio is 14.09. In terms of profitability, NXL's ROE is -2.78%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NXL is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
NXL vs EW Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, EW has a market cap of 49.7B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while EW trades at $86.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas EW's P/E ratio is 31.99. In terms of profitability, NXL's ROE is -2.78%, compared to EW's ROE of +0.10%. Regarding short-term risk, NXL is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for NXL.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
NXL vs DXCM Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, DXCM has a market cap of 32.6B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while DXCM trades at $86.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas DXCM's P/E ratio is 33.84. In terms of profitability, NXL's ROE is -2.78%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, NXL is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for NXL.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
NXL vs GEHC Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, GEHC has a market cap of 29.5B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while GEHC trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas GEHC's P/E ratio is 14.34. In terms of profitability, NXL's ROE is -2.78%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, NXL is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for NXL.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
NXL vs PHG Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, PHG has a market cap of 23.9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while PHG trades at $24.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas PHG's P/E ratio is 13.96. In terms of profitability, NXL's ROE is -2.78%, compared to PHG's ROE of +0.10%. Regarding short-term risk, NXL is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for NXL.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
NXL vs ZBH Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ZBH has a market cap of 17.2B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ZBH trades at $88.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ZBH's P/E ratio is 10.48. In terms of profitability, NXL's ROE is -2.78%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NXL is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
NXL vs ABMD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NXL's ROE is -2.78%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NXL is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
NXL vs SWAV Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NXL's ROE is -2.78%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NXL is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
NXL vs PEN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while PEN trades at $318.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas PEN's P/E ratio is 83.12. In terms of profitability, NXL's ROE is -2.78%, compared to PEN's ROE of +0.11%. Regarding short-term risk, NXL is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
NXL vs SNN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SNN trades at $26.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SNN's P/E ratio is 18.21. In terms of profitability, NXL's ROE is -2.78%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NXL is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SNN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
NXL vs BIO-B Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BIO-B trades at $382.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BIO-B's P/E ratio is -67.37. In terms of profitability, NXL's ROE is -2.78%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, NXL is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BIO-B's competition here
Align Technology, Inc. (NASDAQ: ALGN)
NXL vs ALGN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ALGN trades at $145.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ALGN's P/E ratio is 13.25. In terms of profitability, NXL's ROE is -2.78%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, NXL is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
NXL vs BIO Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BIO trades at $377.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BIO's P/E ratio is 40.74. In terms of profitability, NXL's ROE is -2.78%, compared to BIO's ROE of +0.03%. Regarding short-term risk, NXL is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
NXL vs GMED Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while GMED trades at $74.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas GMED's P/E ratio is 16.87. In terms of profitability, NXL's ROE is -2.78%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NXL is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for NXL.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
NXL vs BRKR Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BRKR has a market cap of 9.9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BRKR trades at $64.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BRKR's P/E ratio is 32.54. In terms of profitability, NXL's ROE is -2.78%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, NXL is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BRKR's competition here
Glaukos Corporation (NYSE: GKOS)
NXL vs GKOS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while GKOS trades at $164.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas GKOS's P/E ratio is -191.02. In terms of profitability, NXL's ROE is -2.78%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, NXL is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for NXL.Check GKOS's competition here
Bruker Corporation (NASDAQ: BRKRP)
NXL vs BRKRP Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BRKRP trades at $471.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BRKRP's P/E ratio is 256.03. In terms of profitability, NXL's ROE is -2.78%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, NXL is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BRKRP's competition here
Masimo Corporation (NASDAQ: MASI)
NXL vs MASI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas MASI's P/E ratio is 44.43. In terms of profitability, NXL's ROE is -2.78%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NXL is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for NXL.Check MASI's competition here
Insulet Corp. (NASDAQ: PODD)
NXL vs PODD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, PODD has a market cap of 9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while PODD trades at $130.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas PODD's P/E ratio is 22.23. In terms of profitability, NXL's ROE is -2.78%, compared to PODD's ROE of +0.27%. Regarding short-term risk, NXL is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check PODD's competition here
Haemonetics Corporation (NYSE: HAE)
NXL vs HAE Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while HAE trades at $105.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas HAE's P/E ratio is 21.03. In terms of profitability, NXL's ROE is -2.78%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NXL is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for NXL.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
NXL vs NARI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas NARI's P/E ratio is -59.24. In terms of profitability, NXL's ROE is -2.78%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NXL is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for NXL.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
NXL vs ITGR Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ITGR trades at $126.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ITGR's P/E ratio is 19.90. In terms of profitability, NXL's ROE is -2.78%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, NXL is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
NXL vs LIVN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while LIVN trades at $76.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas LIVN's P/E ratio is 18.17. In terms of profitability, NXL's ROE is -2.78%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, NXL is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
NXL vs IRTC Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while IRTC trades at $113.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas IRTC's P/E ratio is -264.33. In terms of profitability, NXL's ROE is -2.78%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, NXL is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for NXL.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
NXL vs AXNX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NXL's ROE is -2.78%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NXL is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
NXL vs TMDX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while TMDX trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas TMDX's P/E ratio is 42.36. In terms of profitability, NXL's ROE is -2.78%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, NXL is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
NXL vs NEOG Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while NEOG trades at $12.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas NEOG's P/E ratio is 45.65. In terms of profitability, NXL's ROE is -2.78%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, NXL is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for NXL.Check NEOG's competition here
Butterfly Network, Inc. (NYSE: BFLY)
NXL vs BFLY Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BFLY trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BFLY's P/E ratio is -37.29. In terms of profitability, NXL's ROE is -2.78%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, NXL is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BFLY's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
NXL vs UFPT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while UFPT trades at $296.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas UFPT's P/E ratio is 30.32. In terms of profitability, NXL's ROE is -2.78%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NXL is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check UFPT's competition here
AxoGen, Inc. (NASDAQ: AXGN)
NXL vs AXGN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while AXGN trades at $41.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas AXGN's P/E ratio is 110.32. In terms of profitability, NXL's ROE is -2.78%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, NXL is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
NXL vs NUVA Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas NUVA's P/E ratio is 75.00. In terms of profitability, NXL's ROE is -2.78%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, NXL is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for NXL.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
NXL vs INSP Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while INSP trades at $69.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas INSP's P/E ratio is 30.56. In terms of profitability, NXL's ROE is -2.78%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NXL is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for NXL.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
NXL vs ESTA Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ESTA trades at $64.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ESTA's P/E ratio is -50.93. In terms of profitability, NXL's ROE is -2.78%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, NXL is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
NXL vs NVCR Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while NVCR trades at $15.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas NVCR's P/E ratio is -12.27. In terms of profitability, NXL's ROE is -2.78%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, NXL is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for NXL.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
NXL vs ATEC Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ATEC trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ATEC's P/E ratio is -172.00. In terms of profitability, NXL's ROE is -2.78%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, NXL is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
NXL vs CNMD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CNMD trades at $46.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CNMD's P/E ratio is 10.17. In terms of profitability, NXL's ROE is -2.78%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, NXL is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
NXL vs HSKA Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NXL's ROE is -2.78%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NXL is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for NXL.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
NXL vs IART Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while IART trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas IART's P/E ratio is 6.90. In terms of profitability, NXL's ROE is -2.78%, compared to IART's ROE of -0.01%. Regarding short-term risk, NXL is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for NXL.Check IART's competition here
Avanos Medical, Inc. (NYSE: AVNS)
NXL vs AVNS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas AVNS's P/E ratio is 27.77. In terms of profitability, NXL's ROE is -2.78%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NXL is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for NXL.Check AVNS's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
NXL vs TNDM Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while TNDM trades at $16.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas TNDM's P/E ratio is -17.54. In terms of profitability, NXL's ROE is -2.78%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, NXL is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for NXL.Check TNDM's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
NXL vs SILK Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SILK's P/E ratio is -18.96. In terms of profitability, NXL's ROE is -2.78%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NXL is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
NXL vs AORT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while AORT trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas AORT's P/E ratio is 38.08. In terms of profitability, NXL's ROE is -2.78%, compared to AORT's ROE of -0.01%. Regarding short-term risk, NXL is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check AORT's competition here
IRadimed Corporation (NASDAQ: IRMD)
NXL vs IRMD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while IRMD trades at $86.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas IRMD's P/E ratio is 43.33. In terms of profitability, NXL's ROE is -2.78%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NXL is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
NXL vs FNA Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas FNA's P/E ratio is -19.83. In terms of profitability, NXL's ROE is -2.78%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NXL is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for NXL.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
NXL vs ENOV Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ENOV trades at $18.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ENOV's P/E ratio is 5.23. In terms of profitability, NXL's ROE is -2.78%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, NXL is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ENOV's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
NXL vs PRCT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while PRCT trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas PRCT's P/E ratio is -9.39. In terms of profitability, NXL's ROE is -2.78%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, NXL is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check PRCT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
NXL vs LMRI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, LMRI has a market cap of 984.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while LMRI trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas LMRI's P/E ratio is -19.94. In terms of profitability, NXL's ROE is -2.78%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NXL is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for NXL.Check LMRI's competition here
CeriBell, Inc. (NASDAQ: CBLL)
NXL vs CBLL Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CBLL has a market cap of 925.4M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CBLL trades at $24.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CBLL's P/E ratio is -13.86. In terms of profitability, NXL's ROE is -2.78%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, NXL is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
NXL vs BVS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BVS has a market cap of 923.4M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BVS trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BVS's P/E ratio is 17.93. In terms of profitability, NXL's ROE is -2.78%, compared to BVS's ROE of +0.28%. Regarding short-term risk, NXL is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BVS's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
NXL vs BBNX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BBNX has a market cap of 853.9M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BBNX trades at $18.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BBNX's P/E ratio is -11.50. In terms of profitability, NXL's ROE is -2.78%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, NXL is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
NXL vs CSII Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CSII's P/E ratio is -20.83. In terms of profitability, NXL's ROE is -2.78%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NXL is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
NXL vs SIBN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SIBN has a market cap of 833.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SIBN trades at $18.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SIBN's P/E ratio is -55.29. In terms of profitability, NXL's ROE is -2.78%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, NXL is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SIBN's competition here
InMode Ltd. (NASDAQ: INMD)
NXL vs INMD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, INMD has a market cap of 814.5M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while INMD trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas INMD's P/E ratio is 9.84. In terms of profitability, NXL's ROE is -2.78%, compared to INMD's ROE of +0.12%. Regarding short-term risk, NXL is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
NXL vs VREX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while VREX trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas VREX's P/E ratio is 19.42. In terms of profitability, NXL's ROE is -2.78%, compared to VREX's ROE of +0.05%. Regarding short-term risk, NXL is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check VREX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
NXL vs CTKB Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CTKB has a market cap of 769.7M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CTKB trades at $5.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CTKB's P/E ratio is -31.57. In terms of profitability, NXL's ROE is -2.78%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, NXL is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CTKB's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
NXL vs AHCO Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, AHCO has a market cap of 767.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while AHCO trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas AHCO's P/E ratio is 11.51. In terms of profitability, NXL's ROE is -2.78%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, NXL is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for NXL.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
NXL vs AVR Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, AVR has a market cap of 755.5M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while AVR trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas AVR's P/E ratio is -4.01. In terms of profitability, NXL's ROE is -2.78%, compared to AVR's ROE of -0.78%. Regarding short-term risk, NXL is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for NXL.Check AVR's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
NXL vs PACB Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, PACB has a market cap of 736.1M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while PACB trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas PACB's P/E ratio is -5.78. In terms of profitability, NXL's ROE is -2.78%, compared to PACB's ROE of -49.62%. Regarding short-term risk, NXL is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for NXL.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
NXL vs SRDX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NXL's ROE is -2.78%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NXL is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SRDX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
NXL vs SSII Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SSII has a market cap of 596.4M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SSII trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SSII's P/E ratio is -49.67. In terms of profitability, NXL's ROE is -2.78%, compared to SSII's ROE of -0.27%. Regarding short-term risk, NXL is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SSII's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
NXL vs APEN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas APEN's P/E ratio is -9.43. In terms of profitability, NXL's ROE is -2.78%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NXL is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
NXL vs KIDS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, KIDS has a market cap of 572M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while KIDS trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas KIDS's P/E ratio is -18.87. In terms of profitability, NXL's ROE is -2.78%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, NXL is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for NXL.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
NXL vs DCTH Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, DCTH has a market cap of 551.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while DCTH trades at $15.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas DCTH's P/E ratio is 1597.00. In terms of profitability, NXL's ROE is -2.78%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, NXL is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for NXL.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
NXL vs ZIMV Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NXL's ROE is -2.78%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, NXL is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ZIMV's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
NXL vs SGHT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SGHT has a market cap of 509.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SGHT trades at $9.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SGHT's P/E ratio is -16.71. In terms of profitability, NXL's ROE is -2.78%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, NXL is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SGHT's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
NXL vs TCMD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, TCMD has a market cap of 502.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while TCMD trades at $22.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas TCMD's P/E ratio is 20.64. In terms of profitability, NXL's ROE is -2.78%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, NXL is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
NXL vs CERS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CERS has a market cap of 479.6M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CERS trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CERS's P/E ratio is -79.07. In terms of profitability, NXL's ROE is -2.78%, compared to CERS's ROE of -0.10%. Regarding short-term risk, NXL is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
NXL vs NPCE Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, NPCE has a market cap of 469.1M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while NPCE trades at $13.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas NPCE's P/E ratio is -24.14. In terms of profitability, NXL's ROE is -2.78%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, NXL is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for NXL.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
NXL vs SENS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SENS has a market cap of 425M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SENS trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SENS's P/E ratio is -4.56. In terms of profitability, NXL's ROE is -2.78%, compared to SENS's ROE of -1.66%. Regarding short-term risk, NXL is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
NXL vs OFIX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, OFIX has a market cap of 380.4M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while OFIX trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas OFIX's P/E ratio is -6.13. In terms of profitability, NXL's ROE is -2.78%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, NXL is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check OFIX's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NXL vs CLPT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CLPT has a market cap of 366.2M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CLPT trades at $12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CLPT's P/E ratio is -10.35. In terms of profitability, NXL's ROE is -2.78%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, NXL is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CLPT's competition here
CapsoVision, Inc. (NASDAQ: CV)
NXL vs CV Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CV has a market cap of 322.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CV trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CV's P/E ratio is -10.25. In terms of profitability, NXL's ROE is -2.78%, compared to CV's ROE of -1.78%. Regarding short-term risk, NXL is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CV's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
NXL vs CATX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, CATX has a market cap of 312.5M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while CATX trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas CATX's P/E ratio is -2.06. In terms of profitability, NXL's ROE is -2.78%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NXL is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check CATX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
NXL vs SMLR Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NXL's ROE is -2.78%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, NXL is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for NXL.Check SMLR's competition here
Avita Medical Inc. (NASDAQ: RCEL)
NXL vs RCEL Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, RCEL has a market cap of 291.5M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while RCEL trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas RCEL's P/E ratio is -8.15. In terms of profitability, NXL's ROE is -2.78%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, NXL is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for NXL.Check RCEL's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NXL vs TMCI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, TMCI has a market cap of 288M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while TMCI trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas TMCI's P/E ratio is -4.72. In terms of profitability, NXL's ROE is -2.78%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, NXL is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for NXL.Check TMCI's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
NXL vs TLSI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, TLSI has a market cap of 265.4M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while TLSI trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas TLSI's P/E ratio is -2.57. In terms of profitability, NXL's ROE is -2.78%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, NXL is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for NXL.Check TLSI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
NXL vs INFU Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, INFU has a market cap of 260.1M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while INFU trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas INFU's P/E ratio is 31.44. In terms of profitability, NXL's ROE is -2.78%, compared to INFU's ROE of +0.15%. Regarding short-term risk, NXL is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for NXL.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
NXL vs MGRM Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NXL's ROE is -2.78%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, NXL is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for NXL.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
NXL vs ELMD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ELMD has a market cap of 231M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ELMD trades at $28.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ELMD's P/E ratio is 21.30. In terms of profitability, NXL's ROE is -2.78%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, NXL is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
NXL vs NVRO Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NXL's ROE is -2.78%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NXL is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for NXL.Check NVRO's competition here
Quantum-Si incorporated (NASDAQ: QSI)
NXL vs QSI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, QSI has a market cap of 211.7M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while QSI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas QSI's P/E ratio is -2.33. In terms of profitability, NXL's ROE is -2.78%, compared to QSI's ROE of -0.47%. Regarding short-term risk, NXL is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for NXL.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
NXL vs PROF Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, PROF has a market cap of 210.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while PROF trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas PROF's P/E ratio is -5.92. In terms of profitability, NXL's ROE is -2.78%, compared to PROF's ROE of -0.56%. Regarding short-term risk, NXL is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for NXL.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
NXL vs RXST Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, RXST has a market cap of 202.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while RXST trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas RXST's P/E ratio is -4.34. In terms of profitability, NXL's ROE is -2.78%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NXL is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for NXL.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
NXL vs BSGM Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NXL's ROE is -2.78%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, NXL is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for NXL.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
NXL vs MDGS Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NXL's ROE is -2.78%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NXL is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for NXL.Check MDGS's competition here
Quanterix Corporation (NASDAQ: QTRX)
NXL vs QTRX Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, QTRX has a market cap of 174.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while QTRX trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas QTRX's P/E ratio is -1.46. In terms of profitability, NXL's ROE is -2.78%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, NXL is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for NXL.Check QTRX's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
NXL vs FOCL Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, FOCL has a market cap of 167.5M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while FOCL trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas FOCL's P/E ratio is -4.32. In terms of profitability, NXL's ROE is -2.78%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, NXL is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for NXL.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
NXL vs STIM Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, STIM has a market cap of 162.8M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while STIM trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas STIM's P/E ratio is -5.32. In terms of profitability, NXL's ROE is -2.78%, compared to STIM's ROE of -1.51%. Regarding short-term risk, NXL is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for NXL.Check STIM's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
NXL vs QIPT Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NXL's ROE is -2.78%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NXL is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for NXL.Check QIPT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
NXL vs LUCD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, LUCD has a market cap of 143.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while LUCD trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas LUCD's P/E ratio is -2.03. In terms of profitability, NXL's ROE is -2.78%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, NXL is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for NXL.Check LUCD's competition here
Inogen, Inc. (NASDAQ: INGN)
NXL vs INGN Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, INGN has a market cap of 142.7M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while INGN trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas INGN's P/E ratio is -5.79. In terms of profitability, NXL's ROE is -2.78%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NXL is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for NXL.Check INGN's competition here
iCAD, Inc. (NASDAQ: ICAD)
NXL vs ICAD Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NXL's ROE is -2.78%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NXL is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
NXL vs HJLI Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas HJLI's P/E ratio is N/A. In terms of profitability, NXL's ROE is -2.78%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, NXL is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for NXL.Check HJLI's competition here
electroCore, Inc. (NASDAQ: ECOR)
NXL vs ECOR Comparison October 2026
Nexalin Technology, Inc. (NASDAQ: NXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NXL stands at 3.1M. In comparison, ECOR has a market cap of 97.6M. Regarding current trading prices, NXL is priced at $4.28 on the NASDAQ, while ECOR trades at $10.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NXL currently has a P/E ratio of -9.11, whereas ECOR's P/E ratio is -6.44. In terms of profitability, NXL's ROE is -2.78%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, NXL is more volatile compared to ECOR. This indicates higher risk in terms of short-term price fluctuations for NXL.Check ECOR's competition here